ERBB2 and breast cancer: Kaplan-Meier survival analysis demonstrated that elevated <i>SYTL4</i> mRNA expression is significantly associated with improved overall survival in HER2-positive breast cancer patients (HR = 0.72; <i>p</i> = 0.034).